Not FDA-approved and NOT compoundable as of July 2026. Removed from the Category 2 do-not-compound list in April 2026 (nomination withdrawn, effective 2026-04-23) — a procedural step, not approval; BPC-157 is NOT Category 1 and is in no FDA interim category. On 2026-07-23 an FDA advisory committee (PCAC) recommended it for the 503A bulks list, against FDA's own reviewers; FDA has not adopted that recommendation, BPC-157 is not on the 503A bulks list, and compounding it is not permitted. Also WADA-prohibited (S0).
not-FDA-approved
WADA status
Prohibited (S0 category — non-approved substances, effective January 2022)
